Form Bio

CASE STUDY: Reducing Immunogenicity Risk with AI/ML Immunogenicity can pose significant safety risks in gene therapies, with CpG islands in the CDS of AAV vectors being a key concern due to their potential to trigger immune responses via TLR9 signaling. Using our AI/ML model, FORMsightAI we optimized the coding sequences (CDS) of a housekeeping gene. This led to the reduction in %CpG peaks without altering %GC content. This approach ensures safer AAV vectors while preserving genetic integrity and manufacturability. 🌟 Learn how AI is redefining safety in gene therapy development. https://hubs.li/Q02ZzjGV0 #GeneTherapy #AI #AAV

🚀 CASE STUDY: AI/ML Codon Optimization Improves Enzymatic Activity by 20% Open-source codon optimization tools typically consider a limited set of parameters, which includes CAI (codon adaptation index), individual codon usage and GC content. In a recent study, we evaluated the impact of expression using vectors optimized using an open-source codon optimization and FORMsightAI optimization. We noted the vector optimized using FORMsightAI outperformed the open-source tool, with a 20% increase in enzymatic activity and mRNA expression. Check out the full scientific case study: https://hubs.li/Q02Y_7tn0 #GeneTherapy #AI #AAV

🚀 CASE STUDY: AI/ML Optimizes AAV CDS, Reducing Genome Truncations Reducing partial genomes is a critical objective in AAV gene therapy development to ensure the production of functional, high-quality therapeutic vectors. Optimizing the CDS of the AAV vector plays a key role in addressing this challenge effectively. We've leveraged our proprietary AI/ML technology, FORMsightAI to optimize the CDS to significantly reduce partial genomes and immunotoxicity risk, and minimize production challenges. By de-risking manufacturing, this innovation streamlines bioprocessing and enhances therapeutic potential. Check out the full scientific case study: https://hubs.li/Q02Y_70p0 #GeneTherapy #AI #AAV #BiotechInnovation

🚀 The promise of CGTs is undeniable—but development challenges like safety, efficacy, and manufacturability can hold programs back. At Form Bio, we leverage AI-driven in silico workflows to de-risk AAV vector design, reducing costly iteration cycles. With our partners like PacBio and Resilience, we’re driving the next wave of CGT innovation. Watch our brief overview video to learn how we do it. https://hubs.li/Q02YYdX80 #AAV #GeneTherapy #AI #InSilico #VectorDevelopment

🚀 Advances in AAV Manufacturing for Gene Therapy! Gene therapy has made incredible strides, but scaling up AAV production for broad accessibility is still a challenge. From plasmid construction to AAV vector production and purification, each step impacts therapeutic quality and cost. Our blog dives into the nuances of the AAV manufacturing process and the innovative solutions helping to optimize production, reduce impurities, and ensure therapeutic efficacy. Discover how advances like Form Bio’s AI-driven In Silico Assays™ and new methods in quality control are paving the way for efficient, scalable gene therapy. Read more! https://hubs.li/Q02YhLYD0 #genetherapy #AAV #AI #insilico

🚨 Last chance to register! 🚨 Calling all Boston-based gene therapy professionals! Don’t miss the AAV Innovation Summit 2024—a unique opportunity to dive into the latest advancements in optimizing genome integrity through AI and vector design. 🗓 Date: November 6, 2024 🕘 Time: 8:30am-1pm EST 📍 Location: Cambridge, MA This exclusive half-day summit brings together top experts, including Tim Hunt (Alliance for Regenerative Medicine), Phillip Tai, PhD (UMass Medical School), Adam Cockrell, PhD (Solid Biosciences), and Nithya Jesuraj, PhD (Resilience). Plus, join an engaging panel with members of the AAV Working Group as they discuss open-source tools and standardized methods to elevate key quality metrics in AAV gene therapy. ⚡ Space is limited—Register today! https://hubs.li/Q02Wt-sx0 #genetherapy #aav #innovation #vectordesign #AI #insilico

🚀 Exciting news: the Long-read AAV Analysis (LAAVA) pipeline has reached version 3.0! 🎉 https://hubs.li/Q02WnXpj0 In collaboration with the AAV Working Group, Form Bio has introduced a new AAV sequencing nomenclature to make reports even more interpretable and actionable. This update pays special attention to "snapback" vector genomes, a critical feature highlighted in recent studies. LAAVA 3.0 also includes a refined data schema designed for seamless integration with data/ML engineering workflows, visual dashboards, and custom pipelines. A huge thank you to Elizabeth Tseng, PhD, Nadia Sellami, Ph.D., Amicia D. Elliott, Ph.D., Alpha Boubacar Diallo, Brandi Cantarel, Phillip Tai, Claire Aldridge, Pranam Chatterjee, Adam Cockrell, Eric Talevich and the entire AAV Working Group for their invaluable insights and discussions. We can’t wait to see how this helps move your work forward—let us know what you think!

Check out the AAV Resource Hub, your one-stop shop for advancing and unifying the AAV community, brought to you by Form Bio and PacBio. The hub features an AAV data dictionary, open-source tools, best practices, standards, and more—driven by a newly formed AAV Working Group. AAV is one of the most promising technologies for gene therapy due to its non-pathogenic nature. However, industry silos have created divergent terminology and methods, making collaboration difficult. The lack of standard definitions and practices also complicates regulatory submissions, slowing the evaluation of potential new therapies. https://hubs.li/Q02RnR5D0 #AAV #genetherapy #hifisequencing #vectordesign #AI

Join us for an exclusive half-day summit in Cambridge, MA on November 6th. We're bringing together top industry and academic experts, including Tim Hunt (Alliance for Regenerative Medicine), Phillip Tai, PhD (UMass Chan Medical School), Adam Cockrell, PhD (Solid Biosciences), and Nithya Jesuraj, PhD (Resilience), Nadia Sellami, Ph.D. (PacBio), and Amicia D. Elliott, Ph.D. & Alpha Boubacar Diallo, PhD (Form Bio). Additionally, a panel featuring members of the AAV Working Group, who recently published a key paper and presented at ASGCT, will discuss open-source tools and standardized methods designed to enhance key quality metrics in AAV gene therapy. #AAV #genetherapy #vectordesign #biotech

Species-specific codon optimization has been an invaluable tool in research over the past decades. However, in this case study, we compare the performance of our AI/ML model with an open-source tool for optimizing the activity of an enzyme. Our AI/ML model achieved a 20% increase in mRNA transcript levels and enzyme activity. Explore the methods and results: https://hubs.li/Q02RnHMy0 #CDSoptimization #AI #InSilico #genetherapy